AYTU BIOPHARMA, INC.

Join this Action
Practice Area:
Stock Symbol: AYTU
Case Status: Investigations

Ademi LLP is investigating whether the proposed acquisition of Aytu (NASDAQ: AYTU) by Rosemont Pharmaceuticals, provides fair value to Aytu’s public shareholders and whether Aytu’s Board adequately protected shareholder interests in negotiating and approving the transaction.

What Is Ademi LLP Investigating?

  • The purchase price and whether it adequately reflects Aytu’s value and future prospects;
  • Substantial change-of-control benefits available to Aytu insiders in connection with the transaction;
  • Restrictions on competing transactions, including a significant termination penalty that may discourage another potential buyer from making a superior proposal; and
  • The conduct of Aytu’s Board of Directors in negotiating and approving the transaction and whether the Board fulfilled its duties to public shareholders.

 

Join this Action